[B026] 临床研究方案与设计
通过临床试验id或者登记号获取临床研究方案与设计
clinical_trial_id 和 register_number 两个参数必须传一个
请求参数
此 API 接口支持的参数列表
| 名称 | 类型 | 示例 | 描述 |
|---|---|---|---|
| string | 202425a889e52ae802432a8295220e53 | 临床试验id,通过临床试验检索接口获取 |
| string | NCT06498986 | 登记号 |
响应结构
API 响应数据的结构说明
| 字段名 | 类型 | 示例 | 描述 |
|---|---|---|---|
data | object | - | 响应数据 |
masking | string | None (Open Label) | 盲法 |
outcome | array | [
{
"title": "Recommended Phase II Dose (RP2D)",
"time_frame": "Up to approximately 24 months",
"description": "The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-B01D1.",
"outcome_type": "Primary"
},
{
"title": "Objective response rate (ORR)",
"time_frame": "Up to approximately 24 months",
"description": "ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions). The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1.",
"outcome_type": "Primary"
}
] | 终点指标 |
title | string | Recommended Phase II Dose (RP2D) | 指标 |
time_frame | string | Up to approximately 24 months | 期限 |
description | string | The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-B01D1. | 详情 |
outcome_type | string | Primary | 指标类型 |
allocation | string | N/A | 随机化 |
enrollment | array | [
{
"enrollment": "40"
}
] | 招募人数 |
location | string | Domestic | 位置,Domestic:中国;International:国际 |
enrollment | string | 98 | 招募人数 |
enrollment_text | string | 国内:150 | 招募人数原始值 |
enrollment_type | string | Anticipated | 招募类型 |
start_date | object | {
"time_ts": 1722470400000,
"date_type": "Anticipated"
} | 开始日期 |
time_ts | integer<int64> | 1785542400000 | 日期时间戳 |
date_type | string | Anticipated | 日期类型,枚举值:Anticipated,Actual |
study_type | string | Interventional | 试验类型,枚举值:"Prevention","Expanded Access","Health Services Research","Interventional","Prognosis","Cause","Observational","Basic Science","Unknown","Others" |
completion_date | object | {
"time_ts": 1785542400000,
"date_type": "Anticipated"
} | 试验完成日期 |
primary_purpose | string | Treatment | 主要目的 |
register_number | string | NCT06498986 | 登记号 |
arm_intervention | array | [
{
"intervention": [
{
"intervention_name": "BL-B01D1",
"intervention_type": "Drug",
"intervention_description": "Administration by intravenous infusion for a cycle of 3 weeks."
},
{
"intervention_name": "Osimertinib Mesylate Tablets",
"intervention_type": "Drug",
"intervention_description": "Oral administration, 80mg daily for a cycle of 3 weeks."
}
],
"design_group_type": "Experimental",
"design_group_title": "BL-B01D1+Osimertinib Mesylate Tablets",
"design_group_description": "Participants receive BL-B01D1+Osimertinib Mesylate Tablets in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons."
}
] | 分组与干预 |
intervention | array | [
{
"intervention_name": "BL-B01D1",
"intervention_type": "Drug",
"intervention_description": "Administration by intravenous infusion for a cycle of 3 weeks."
},
{
"intervention_name": "Osimertinib Mesylate Tablets",
"intervention_type": "Drug",
"intervention_description": "Oral administration, 80mg daily for a cycle of 3 weeks."
}
] | 干预 |
intervention_name | string | BL-B01D1 | 干预名称 |
intervention_type | string | Drug | 干预类型 |
intervention_description | string | Administration by intravenous infusion for a cycle of 3 weeks. | 干预详情 |
design_group_type | string | Experimental | 分组类型 |
design_group_title | string | BL-B01D1+Osimertinib Mesylate Tablets | 分组标题 |
design_group_description | string | Participants receive BL-B01D1+Osimertinib Mesylate Tablets in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons. | 分组详情 |
clinical_trial_id | string | 202425a889e52ae802432a8295220e53 | 临床试验ID |
first_posted_date | integer<int64> | 1720742400000 | 首次公示日期 |
intervention_model | string | Single Group Assignment | 设计类型 |
primary_completion_date | object | {
"time_ts": 1785542400000,
"date_type": "Anticipated"
} | 主要终点完成日期 |
status必填 | boolean | false | 状态 |
error_msg | string | The request parameter format is incorrect! | 错误信息 |
error_code必填 | integer | 0 | 错误代码 |
成功响应示例
成功调用 API 的响应示例
JSON
{
"data": {
"masking": "None (Open Label)",
"outcome": [
{
"title": "Recommended Phase II Dose (RP2D)",
"time_frame": "Up to approximately 24 months",
"description": "The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-B01D1.",
"outcome_type": "Primary"
}
],
"allocation": "N/A",
"enrollment": [
{
"location": "Domestic",
"enrollment": 98,
"enrollment_text": "国内:150",
"enrollment_type": "Anticipated"
}
],
"start_date": {
"time_ts": 1785542400000,
"date_type": "Anticipated"
},
"study_type": "Interventional",
"completion_date": {
"time_ts": 1785542400000,
"date_type": "Anticipated"
},
"primary_purpose": "Treatment",
"register_number": "NCT06498986",
"arm_intervention": [
{
"intervention": [
{
"intervention_name": "BL-B01D1",
"intervention_type": "Drug",
"intervention_description": "Administration by intravenous infusion for a cycle of 3 weeks."
}
],
"design_group_type": "Experimental",
"design_group_title": "BL-B01D1+Osimertinib Mesylate Tablets",
"design_group_description": "Participants receive BL-B01D1+Osimertinib Mesylate Tablets in the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons."
}
],
"clinical_trial_id": "202425a889e52ae802432a8295220e53",
"first_posted_date": 1720742400000,
"intervention_model": "Single Group Assignment",
"primary_completion_date": {
"time_ts": 1785542400000,
"date_type": "Anticipated"
}
},
"status": true,
"error_code": 0
}错误码
此接口可能返回的错误码列表
业务错误码
| 错误码 | 描述 |
|---|---|
68300004 | 请求参数异常! |
68300005 | 查询Api失败! |
68300006 | 解析基本存取错误! |
68300007 | 存在错误的请求! |
68300008 | 服务中断异常,请稍后再试! |
68300010 | 文件不符合上传规范! |
平台错误码
| 错误码 | 描述 |
|---|---|
67200001 | API整体限流错误! |
67200002 | 用户调用请求限流限制错误! |
67200003 | 申请token的key和secret不正确或者状态错误! |
67200004 | 无权限或该接口的套餐已超过系统设置的上限! |
67200005 | 账户余额不足,调用失败! |
67200006 | 客户端已过期,调用失败! |
67200007 | 超过调用额度,调用失败! |
HTTP 状态码
| 状态码 | 描述 |
|---|---|
0 | 请求成功 |
401 | Unauthorized |
403 | Forbidden |
404 | Not Found |
性能指标
此接口的预期性能特征
正常响应时间
5000 ms
最大响应时间
10000 ms